Benefits and risks of preventing thromboembolism with enoxaparin in patients with general surgery in real world - The CLEVER study

Clinical and Applied Thrombosis/Hemostasis

Volumn 19, Issue 3, 2013, Pages 282-288

  Schellong, Sebastian M ^a   Encke, Albrecht ^b   Weber, Artur Aaron ^c   Bramlage, Peter ^d   Paar, W Dieter ^e   Haas, Sylvia ^f  

^a ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^d Institute für Pharmakologie und Präventive Medizin   (Germany)

^e SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

complete compression ultrasound; enoxaparin; major bleeding; predictors; surgery; venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DIPYRIDAMOLE; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEMOGLOBIN; NONSTEROID ANTIINFLAMMATORY AGENT; TICLOPIDINE;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; COMPLETE COMPRESSION ULTRASOUND; COMPRESSION BANDAGE; COMPRESSION STOCKING; DEEP VEIN THROMBOSIS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEMALE; FOLLOW UP; GENERAL SURGERY; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMOBILIZATION; INDWELLING CATHETER; INTRAOCULAR HEMORRHAGE; INTRAVASCULAR ULTRASOUND; KIDNEY DISEASE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPHYLAXIS; RECOMMENDED DRUG DOSE; RISK FACTOR; SURGICAL PATIENT; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

COMPLETE COMPRESSION ULTRASOUND; ENOXAPARIN; MAJOR BLEEDING; PREDICTORS; SURGERY; VENOUS THROMBOEMBOLISM;

ADULT; AGED; ANTICOAGULANTS; ENOXAPARIN; FEMALE; HUMANS; MALE; MIDDLE AGED; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 84878849340     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029612461067     Document Type: Article

References (27)

1. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ. 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 2012 ; 141 (2 suppl). 7S - 47S
2. Simonneau G, Laporte S, Mismetti P, et al. A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer. J Thromb Haemost. 2006 ; 4 (8). 1693-1700
3. Nurmohamed MT, Verhaeghe R, Haas S, et al. A comparative trial of a low molecular weight heparin (enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery. Am J Surg. 1995 ; 169 (6). 567-571
4. Gazzaniga GM, Angelini G, Pastorino G, Santoro S, Lucchini M, Dal Pra ML. Enoxaparin in the prevention of deep venous thrombosis after major surgery: multicentric study. The Italian Study Group. Int Surg. 1993 ; 78 (3). 271-275
5. Ho YH, Seow-Choen F, Leong A, Eu KW, Nyam D, Teoh MK. Randomized, controlled trial of low molecular weight heparin vs. no deep vein thrombosis prophylaxis for major colon and rectal surgery in Asian patients. Dis Colon Rectum. 1999 ; 42 (2). 196-202
6. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. [ENOXACAN Study Group]. Br J Surg. 1997 ; 84 (8). 1099-1103
7. Kaaja R, Lehtovirta P, Venesmaa P, et al. Comparison of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin, with or without dihydroergotamine, in abdominal hysterectomy. Eur J Obstet Gynecol Reprod Biol. 1992 ; 47 (2). 141-145
8. Samama M, Bernard P, Bonnardot JP, Combe-Tamzali S, Lanson Y, Tissot E. Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis. Br J Surg. 1988 ; 75 (2). 128-131
9. Combe S, Samama MM. Prevention of thromboembolic disease in general surgery with clexane (enoxaparin). Semin Thromb Hemost. 1991 ; 17 (suppl 3). 291-295
10. Samama M, Combe S. Prevention of thromboembolic disease in general surgery with enoxaparin (Clexane). Acta Chir Scand Suppl. 1990 ; 556: 91-95
11. Samama M, Combe-Tamzali S. Prevention of thromboembolic disease in general surgery with enoxaparin. Br J Clin Pract Suppl. 1989 ; 65: 9-15
12. McLeod RS, Geerts WH, Sniderman KW, et al. Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the canadian colorectal DVT prophylaxis trial: a randomized, double-blind trial. Ann Surg. 2001 ; 233 (3). 438-444
13. Schellong S, Hesselschwerdt HJ, Paar WD, von Hanstein KL. Rates of proximal deep vein thrombosis as assessed by compression ultrasonography in patients receiving prolonged thromboprophylaxis with low molecular weight heparin after major orthopedic surgery. Thromb Haemost. 2005 ; 94 (3). 532-536
14. Mismetti P, Laporte S, Darmon JY, Buchmuller A, Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg. 2001 ; 88 (7). 913-930
15. Samama MM. Prevention of postoperative thromboembolism in general surgery with enoxaparin. Eur J Surg Suppl. 1994 ; (571). 31-33
16. Haas S, Wolf H, Kakkar AK, Fareed J, Encke A. Prevention of fatal pulmonary embolism and mortality in surgical patients: a randomized double-blind comparison of LMWH with unfractionated heparin. Thromb Haemost. 2005 ; 94 (4). 814-819
17. Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med. 2006 ; 144 (9). 673-684
18. Collet JP, Montalescot G, Agnelli G, et al. Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events. Eur Heart J. 2005 ; 26 (21). 2285-2293
19. Gibson CM, Dumaine RL, Gelfand EV, et al. Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials. Eur Heart J. 2004 ; 25 (22). 1998-2005
20. Buller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003 ; 349 (18). 1695-1702
21. Brown ML, Gersh BJ, Holmes DR, Bailey KR, Sundt TM. From randomized trials to registry studies: translating data into clinical information. Nat Clin Pract Cardiovasc Med. 2008 ; 5 (10). 613-620
22. Schellong SM, Beyer J, Kakkar AK, et al. Ultrasound screening for asymptomatic deep vein thrombosis after major orthopaedic surgery: the VENUS study. J Thromb Haemost. 2007 ; 5 (7). 1431-1437
23. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004 ; 110 (7). 874-879
24. Hull RD, Schellong SM, Tapson VF, et al. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med. 2010 ; 153 (1). 8-18
25. Hull RD, Schellong SM, Tapson VF, et al. Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: methodology for the EXCLAIM study. J Thromb Thrombolysis. 2006 ; 22 (1). 31-38
26. Goldhaber SZ, Leizorovicz A, Kakkar AK, et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011 ; 365 (23). 2167-2177
27. Schellong SM. Venous ultrasonography in symptomatic and asymptomatic patients: an updated review. Curr Opin Pulm Med. 2008 ; 14 (5). 374-380